stockrow
Saturday 7 November 2026
Export LIPO’s income statement to Excel — free account
Lipella Pharmaceuticals Inc.
LIPO Healthcare Biotechnology
Lipella Pharmaceuticals Inc.’s revenue for fiscal 2024 (year ended December 2024) was $536,400.00, up 19.3% from fiscal 2023.
- Revenue
- −36.4%
- EPS
- +78.3%
- Free cash flow
- −41.8%
Quarter to September 2025, against a year earlier
0.00
0.00
NaN
Follow LIPO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM Sep ’25 | Trend | 10 yrs | 2025e | 2026e | 2027e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 1 | 1 | 0 | 0 | 0 | 1 | 0 | (5.0%) | 0 | 0 | — | (17.7%) | |
| Gross margin, % | — | — | — | — | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | — | — | 0 | 0 | (2) | (3) | (5) | (5) | (5) | +140.9% | ||||||
| EBT margin, % | — | — | — | — | (8.90) | (6.42) | (719.44) | (1,410.26) | (1,027.36) | (935.18) | 0.00 | (926.3) pt | ||||||
| Net income | — | — | — | — | 0 | 0 | (2) | (3) | (5) | (5) | (5) | +140.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.12 | 1.44 | 0.61 | 0.36 | 0.60 | 0.51 | 0.00 | +33.2% | |||||
| Earnings | — | — | — | — | (0.01) | (0.09) | (4.38) | (5.12) | (6.16) | (4.79) | (2.42) | +243.6% | ||||||
| Cash flow | — | — | — | — | (0.01) | (0.04) | (2.32) | (3.61) | (4.20) | (3.77) | (1.05) | +252.8% | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | (0.01) | (0.04) | (2.32) | (3.61) | (4.22) | (3.77) | (1.05) | +252.8% | ||||||
| Book value | — | — | — | — | (0.02) | 0.70 | 3.34 | 9.21 | 4.19 | 1.83 | 0.33 | n/m | ||||||
| Shares, m | — | — | — | — | 6 | 1 | 0 | 1 | 1 | 1 | 3 | (28.7%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 12.56 | 5.96 | 0.00 | 3.1 | ||||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 2.78 | 1.80 | 1.67 | 0.00 | 1.0 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 5.90 | 2.45 | (3.31) | 1.4 | ||||||
| EV/FCF | — | — | — | — | (9.13) | (9.13) | (9.13) | (4.46) | (0.84) | (0.33) | 0.32 | (5.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | 0 | (1) | (2) | (3) | (4) | (5) | +151.7% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | — | 0 | — | ||||||
| Free cash flow | — | — | — | — | 0 | 0 | (1) | (2) | (3) | (4) | (5) | +151.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 0 | 1 | 5 | 3 | 2 | 1 | n/m | |||||
| Net debt | — | — | — | — | 0 | 0 | (2) | (5) | (3) | (2) | (2) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | 0 | 0 | 1 | 5 | 3 | 2 | 1 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (11.49) | (125.71) | (65.24) | (96.96) | (160.49) | (236.36) | (160.5) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | 0.00 | (35.80) | (197.76) | (85.18) | (118.13) | (198.12) | (361.77) | (198.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 5 | 7 | 7 | 7 | — | +11.9% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.05 | 0.03 | 0.06 | 0.08 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Jun 2025 · fundamentals updated 25 Oct 2026
Lipella Pharmaceuticals Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CVKD Cadrenal Therapeutics, Inc. | $3.6M | — (loss-making) | — | — | n/m | +26.24% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LIMN Liminatus Pharma Inc. | $3.5M | — (loss-making) | — | — | n/m | +89.00% (above 0%: growing) | — | 0.00% | Compare |
| LIPO Lipella Pharmaceuticals Inc. | $3.4M | — (loss-making) | — (loss-making) | −36.44% (below 0%: shrinking) | n/m | −41.79% (below 0%: shrinking) | 100.00% | 0.00% | |
| GRI GRI Bio, Inc. | $3.4M | — (loss-making) | — (loss-making) | — | n/m | +54.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TRAW Traws Pharma, Inc. | $3.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −25.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| ONCO Onconetix, Inc. | $3.2M | — (loss-making) | — (loss-making) | −83.94% (below 0%: shrinking) | n/m | −36.00% (below 0%: shrinking) | 25.15% | (15,969.59%) | Compare |
| SXTP 60 Degrees Pharmaceuticals Inc. | $3.2M | — (loss-making) | — (loss-making) | −32.48% (below 0%: shrinking) | n/m | −54.33% (below 0%: shrinking) | 27.32% | (1,092.40%) | Compare |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.1M | — (loss-making) | — (loss-making) | −85.95% (below 0%: shrinking) | n/m | −2.73% (below 0%: shrinking) | (2.67%) | 0.00% | Compare |
| Median of peers | $3.4M | — | — | −84.94% | — | +11.76% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 12 November 2024
Ownership
Directors and executive officers, together
32.11%
Jonathan Kaufman
16.22%
Michael Chancellor
16.02%
Leaf Huang
5.74%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement